Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016

Delcath Systems, Inc. reports financial results for the quarter ended September 30, 2016.

We analyze the earnings along side the following peers of Delcath Systems, Inc. – AngioDynamics, Inc., Insulet Corporation, ICU Medical, Inc., Merit Medical Systems, Inc., Tandem Diabetes Care, Inc., Baxter International Inc. and Teleflex Incorporated (ANGO-US, PODD-US, ICUI-US, MMSI-US, TNDM-US, BAX-US and TFX-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 0.44 million, Net Earnings of USD -1.01 million.
  • Gross margins widened from 59.77% to 74.25% compared to the same period last year, operating (EBITDA) margins now -1,071.49% from -879.45%.
  • Year-on-year change in operating cash flow of -12.32% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings growth due to contribution of one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30
Relevant Numbers (Quarterly)
Revenues (mil) 0.44 0.51 0.37 0.44 0.4
Revenue Growth (%YOY) 9.02 9.66 -16.67 50.86 83.87
Earnings (mil) -1.01 -6.67 -1.81 -5.09 -2.42
Earnings Growth (%YOY) 58.51 -80.24 48.02 -72.94 46.86
Net Margin (%) -231.03 -1304.7 -490 -1160.14 -607.02
EPS -0.66 -4.41 -1.28 -3.74 -1.92
Return on Equity (%) -81.08 -401.38 -88.12 -184.23 -72.77
Return on Assets (%) -10.26 -98.93 -51.32 -115.42 -52.43

Access our Ratings and Scores for Delcath Systems, Inc.

Market Share Versus Profits

Revenues History
Earnings History

DCTH-US‘s change in revenue this period compared to the same period last year of 9.02% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that DCTH-US is holding onto its market share. Also, for comparison purposes, revenues changed by -14.87% and earnings by 84.93% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Earnings Growth Analysis

The company’s earnings growth has been influenced by the year-on-year improvement in gross margins from 59.77% to 74.25%. However the company’s overhead costs have prevented it from fully capitalizing on these gross margin improvements. In fact, the company’s operating margins (EBITDA margins) showed no improvement over the same period last year.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Cash Versus Earnings – Sustainable Performance?

DCTH-US‘s change in operating cash flow of -12.32% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

The company’s operating (EBIT) margins contracted from -914.79% to -1,085.98%. In spite of this, the company’s earnings rose. This was influenced primarily by one-time items, which improved pretax margins from -607.02% to -231.03%.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Delcath Systems, Inc.

Company Profile

Delcath Systems, Inc. is a pharmaceutical and medical device company, which focuses on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The company was founded on August 5, 1988 and is headquartered in New York, NY.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of DCTH-US.